During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.
But how do killer T cells “learn” to leave their home base and amass within specific tissues like the skin, gut, and lung, or solid tumors? Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies.
Writing in the journal Nature, researchers from The Scripps Research Institute and the University of California, San Diego report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.
“Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor,” said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute.
The paper, “Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumors,” appears in Nature’s Dec. 14 issue.
There are two main strategies in cancer immunotherapy that employ killer T cells, Pipkin said. Checkpoint inhibitor blockade unleashes killer T cells, prompting them to accumulate in tumors more aggressively. Adoptive cell transfer, meanwhile, involves re-infusing a patient’s own immune cells after they have been engineered in the lab to recognize and destroy the patient’s specific cancer.
The adoptive cell transfer strategy has worked stunningly well in some blood cancers associated with the lymphoid system, so far. But there appears to be less efficient activity of T cells in solid tumors, Pipkin said.
“The gene programs and signals for how the T cells take up residence in tissues outside of the general circulation was not really well understood,” Pipkin said.
To discover factors that control T cell residency beyond the lymphoid system, Pipkin’s team worked collaboratively with the laboratory of UC San Diego’s Ananda Goldrath, who compared the gene expression of CD8+ T cells found in non-lymphoid tissue to those found in the general circulation. From a list of potential factors, they employed an RNA interference screening strategy which can test the actual function of thousands of factors simultaneously. Pipkin’s lab had developed the screening strategy in collaboration with Shane Crotty at the La Jolla Institute for Allergy and Immunology.
“We found a distinct pattern,” Pipkin said. “The screens showed that Runx3 is one at the top of a list of regulators essential for T cells to reside in nonlymphoid tissues.” Moreover, Runx3 was able to engage a specific gene program that is found in natural tissue-resident and tumor infiltrating CD8+ T cells, he said.
The group further assessed whether Runx3 had a role in directing white blood cells that attack solid tumors in mouse melanoma models. They found that adoptive cell transfer of cancer-specific killer T cells that overexpressed Runx3 delayed tumor growth and prolonged survival, while mouse models treated with those lacking Runx3 fared much worse than normal.
“If we enhance Runx3 activity in the cells, the tumors are significantly smaller and there is greater survival compared to the control group,” Pipkin said.
Knowing that modulating Runx3 activity in T cells influences their ability to reside in solid tumors opens new opportunities for improving cancer immunotherapy, Pipkin said.
“The upshot is we could probably use Runx3 to reprogram adoptively transferred cells to help drive them to amass in solid tumors,” he said. He added that a collaboration of specialists energized the research. “It was a fantastic collaboration, it all came together very quickly,” Pipkin said.
The Latest on: Cancer immunotherapy
‘Big Data’ May Help Immunotherapy
on August 15, 2018 at 12:11 pm
It may be possible to use bioinformatics as a gathering tool to determine how a patient’s immune system responds to immunotherapy. In a study published in Cancer Immunology Research, researchers at th... […]
Immunotherapy Data Lead Lung Cancer Landscape Following ASCO 2018
on August 15, 2018 at 7:27 am
Immunotherapy has risen to the forefront of thoracic oncology; however, challenges exist with comparing checkpoint inhibitors and how to best select patients for this class of agents, whether alone or ... […]
3 Scientists Share $500,000 Prize for Work on Cancer Therapy
on August 15, 2018 at 5:38 am
"Their impact on the development of cancer immunotherapy - and where it goes from here - is unsurpassed." Immunotherapy harnesses the power of the immune system to attack cancer cells and tumors. In t... […]
Media registration: Cancer Immunotherapy Conference in New York
on August 14, 2018 at 1:44 pm
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will spon... […]
Wichita cancer center selected for breast cancer immunotherapy clinical trial
on August 13, 2018 at 8:40 am
The Cancer Center of Kansas has been selected to participate in two clinical trials for immunotherapies being developed for the treatment of advanced breast cancer. Dr. Shaker Dakhil, president of Can... […]
Exosomes from Cancer Cells Could Predict Immunotherapy Responses
on August 12, 2018 at 9:02 pm
A team of researchers from the University of Pennsylvania (UPenn) School of Medicine revealed that the exosomes (extracellular vesicles) that contain programmed death-ligand 1 (PD-L1), released by mel... […]
Immunotherapy Rechallenge Successful in Some Cancer Patients
on August 10, 2018 at 7:12 am
Patients treated with anti–programmed death 1 (PD-1) or anti–programmed death ligand 1 (PD-L1) inhibitors in clinical trials were successfully retreated with the inhibitors after discontinuing the tre... […]
Cancer Immunotherapy Market is growing at a CAGR of 14.42% by 2025 - Progressive Markets
on August 8, 2018 at 4:39 am
Pune, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Progressive Markets published a report, titled, Cancer Immunotherapy Market: Size, Trend, Share, Opportunity Analysis & Forecast, 2018-2025, which projects that ... […]
Cancer Immunotherapy Market – Changing Supply And Demand Scenarios By 2023
on August 8, 2018 at 1:32 am
Market Research Future has announced the addition of the “Global Cancer Immunotherapy Market Research Report which gives Market Size, Shares and Forecasts till 2023. The Cancer Immunotherapy Industry ... […]
Cancer Immunotherapy Market 2018 Booming Cancer Industry by 14.8% CAGR till 2023 with Most Demanding Players
on August 5, 2018 at 11:11 pm
Market Research Future recently published a study report “Cancer Immunotherapy Market”, giving out a complete market insight for the period 2017 – 2023. In its analysis, MRFR asserts that the Global C... […]
via Google News and Bing News